Amodia Bioservice

Executive Summary

Amodia Bioservice GmbH is a private German biotechnology company headquartered in Hamburg, founded in 2008. The company specializes in nucleic-acid-based molecular diagnostic solutions for the detection and identification of microorganisms. Its core offering includes sensitive, fast, and secure diagnostic services and products tailored to customer needs, with a vision of simplifying molecular diagnostics. Despite a long operating history of over 17 years, the company remains privately held with no disclosed funding rounds or valuation, suggesting a bootstrapped or slow-growth trajectory. Amodia competes in the fragmented diagnostics and antibodies market, focusing on niche applications in microbial detection. While the company has a clear specialization, its limited public profile and lack of commercial product counts or FDA approvals indicate a primarily service-oriented business with moderate scalability potential.

Upcoming Catalysts (preview)

• TBDLaunch of new CE-IVD marked diagnostic kit60% success
• TBDStrategic partnership for distribution in EU markets50% success
• TBDExpansion of service portfolio to include next-generation sequencing40% success